On Monday, Shares of Micron Technology, Inc. (NASDAQ:MU), lost -0.72% to $18.03. The stock attained the volume of 22.49 million shares.
The year-to-date (YTD) performance reflected a -48.50% below last year. During the past month the stock gains 7.32%, bringing three-month performance to -8.06% and six-month performance to -34.96%. The stock holds the market capitalization of $-48.50 million.
Chinese state-backed technology conglomerate Tsinghua Unigroup has hired Charles Kau, the chief of Micron Technology Inc’s Taiwanese joint venture, as its global executive vice president, a person familiar with the matter told Reuters.
Kau is the chairman of Inotera Memories Inc, a joint venture between the U.S. company and Taiwan’s Nanya Technology Corp.
Last week Kau resigned from his position as president of Nanya Technology, although he continued as a board member of the company and as chairman of Inotera.
Nanya Technology designated one of its veteran executives, Pei-Ing Lee, as successor. Lee said on Monday during an earnings conference that the company tried to keep Kau and asked him to reconsider his decision.
Kau’s hiring comes about three months after Tsinghua made an informal $23 billion takeover offer for Micron that was rejected out-of-hand by the Idaho-based company’s leadership, although the Chinese side has not given up on a deal, sources have told Reuters.
Micron Technology, Inc., together with its auxiliaries, provides semiconductor solutions worldwide. The company manufactures and markets dynamic random access memory (DRAM), NAND flash, and NOR flash memory products; and packaging solutions and semiconductor systems.
At the end of Monday’s trade, Shares of CSX Corporation (NYSE:CSX), declined -2.44% to $28.37.
Volunteers from CSX and its national service partners City Year, Action for Healthy Kids, and Arbor Day Foundation were joined by community and school representatives on Saturday to improve Sayler Park Elementary School in Cincinnati, Ohio.
Throughout the morning, more than 100 volunteers repaired Sayler’s school garden, improved the playground and outdoor areas, painted murals in the classrooms and outdoors, and planted trees to beautify the environment.
Throughout 2015, CSX has been hosting service days that unite national service partners and local organizations to give back at schools by bettering the environment, community, safety, and health and wellness. These efforts are part of CSX’s #LocalMotive, an ongoing conversation about the company’s presence in the communities it serves through volunteerism, job creation, and moving essential goods.
CSX Corporation, together with its auxiliaries, provides rail-based transportation services in the United States and Canada. It offers traditional rail services, and transports intermodal containers and trailers.
Finally, Shares of Abbott Laboratories (NYSE:ABT), ended its last trade with -0.84% loss, and closed at $41.56.
Abbott (ABT) declared positive one-year clinical results from the ABSORB III trial, which contrast the safety and effectiveness of Abbott’s fully dissolving Absorb™ heart stent to XIENCE ®, Abbott’s market-leading, metallic drug eluting stent. The trial was conducted at 193 sites, primarily in the United States, and enrolled about 2,000 people with coronary artery disease, the most common type of heart disease. The results, which showed that ABSORB III met its primary endpoint and will be used to support regulatory approval of Absorb in the U.S., were featured recently during a late-breaking session at the 27th Transcatheter Cardiovascular Therapeutics (TCT), the annual scientific symposium of the Cardiovascular Research Foundation. In addition, the study results were published simultaneously in The New England Journal of Medicine.
Absorb is a first-of-its-kind device that functions like a permanent, metallic stent by opening a blocked artery in the heart, restoring blood flow and providing relief from symptoms of coronary artery disease (CAD). However, unlike a metallic stent, which permanently restricts vessel movement and limits future treatment options, Absorb is made of a naturally dissolvable material that leaves behind a restored vessel in a natural state, free of a permanent implant. An unrestricted vessel with restored vessel function has the potential to flex, pulse and dilate in response to various demands on the heart, based on people’s lifestyle and activities, and allows for potential future treatment options.
Absorb is accessible in more than 100 countries worldwide and has been used to treat more than 125,000 people. Abbott accomplished its submission for regulatory approval of Absorb in the United States, and it plans to submit for regulatory approval in China. ABSORB III is designed to support regulatory approval of Absorb in the United States, and ABSORB China is designed to support regulatory approval of Absorb in China. Presently, Absorb is an investigational device in the United States and China, and it is not approved for commercial use in these countries.
Abbott Laboratories manufactures and sells health care products worldwide. Its Established Pharmaceutical Products segment offers branded generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency; irritable bowel syndrome; intrahepatic cholestasis or depressive symptoms; gynecological disorders; dyslipidemia; hypertension; hypothyroidism; pain, fever, and inflammation; hormone replacement therapy; anti-infective and influenza vaccines; and product that regulates physiological rhythm of the colon
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
